UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Filed Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported): May 8, 2008
Repros Therapeutics Inc.
(Exact name of registrant as specified in its charter)
| | | | | |
Delaware
(State or other
jurisdiction of
incorporation or
organization) | | 001-15281
(Commission File Number) | | 76-0233274
(I.R.S. Employer Identification No.) |
2408 Timberloch Place, Suite B-7
The Woodlands, Texas 77380
(Address of principal
executive offices
and zip code)
(281) 719-3400
(Registrant’s telephone
number, including area
code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
| | |
| o | | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| o | | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| o | | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| o | | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| | |
| Item 7.01. | | Regulation FD Disclosure |
Repros Therapeutics Inc. (the “Company”) announced today that it will report financial results for the first quarter ended March 31, 2008, on May 9, 2008 after the financial markets close.
Repros management will hold a conference call to discuss its clinical development progress, financial results for the first quarter 2008 and to answer investor questions at 1:00 p.m. Eastern Time on May 12, 2008. Investors can access the call by dialing 866-237-3252 (within the United States) or 719-457-1018 (International). The Passcode is 379126.
| | |
| Item 9.01. | | Financial Statements and Exhibits |
c. Exhibits
| | | | | |
| Exhibit | | |
| Number | | Description |
| | | | | |
| | 99.1 | | | Press Release dated May 8, 2008. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | Repros Therapeutics Inc.
| |
| Date: May 8, 2008 | By: | /s/ Louis Ploth, Jr. | |
| | | Louis Ploth, Jr. | |
| | | Vice President, Business Development and Chief Financial Officer | |
| |
EXHIBIT INDEX
| | | | | |
| Exhibit | | |
| Number | | Description |
| | | | | |
| | 99.1 | | | Press Release dated May 8, 2008 |
